Cellceutix Corp (CTIX) 1.3700 $CTIX
Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data
Marketwire Canada - Wed Aug 03, 8:30AM CDT
BEVERLY, MA--(Marketwired - August 03, 2016) - Cellceutix Corporation, (OTC: CTIX) ("the Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to provide topline data on the completed Phase 1 clinical trial of Kevetrin for the treatment of advanced solid tumors, which are among the hardest-to-treat types of cancers.
Cellceutix Announces Dismissal of Class Action Lawsuit Filed by Rosen Law Firm
Marketwire Canada - Thu Jun 09, 9:51AM CDT
BEVERLY, MA--(Marketwired - June 09, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that, yesterday, the U.S. District Court for the Southern District of New York granted the Company's motion to dismiss the securities class action lawsuit brought against the Company by a plaintiff represented by the Rosen Law Firm.
Cellceutix Announces Database Lock in Phase 1 Trial of Kevetrin, a Promising New Cancer Treatment That Activates p53
Marketwired - Mon Jun 06, 6:01AM CDT
BEVERLY, MA--(Marketwired - June 06, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to announce that the study database from the Phase 1 trial of Kevetrin (thioureidobutyronitrile) for advanced solid tumors will be "soft locked" this week. These locked results are the final protocol requirement for the study of Kevetrin in its next clinical trial and will be added to the already prepared documentation for submission to the U.S. Food and Drug Administration ("FDA" in support of the planned Phase 1b/2 trial of Kevetrin in ovarian cancer patients with resistance to platinum-based therapies. Cellceutix is developing Kevetrin under an Orphan Drug designation from the FDA.
Cellceutix Releases Pharmacokinetics Data From Phase 2 Trial of Prurisol for Treating Psoriasis; Data Complements Efficacy Data Reported Last Week
Marketwired - Tue May 31, 6:00AM CDT
BEVERLY, MA--(Marketwired - May 31, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to announce that the pharmacokinetics (PK) data on the recently completed Phase 2 trial of Prurisol as a novel oral treatment for plaque psoriasis has been received and is starting to be analyzed.
Cellceutix Provides Additional Insight Into Successful Phase 2 Trial for Treating Psoriasis
Marketwire Canada - Thu May 26, 6:01AM CDT
BEVERLY, MA--(Marketwired - May 26, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, today provides additional insight into the successfully completed Phase 2 trial of Prurisol as a new oral therapy for mild to moderate plaque psoriasis.
Cellceutix Phase 2 Trial of Prurisol for Mild to Moderate Psoriasis Meets Primary Endpoint
Marketwired - Tue May 24, 9:01AM CDT
BEVERLY, MA--(Marketwired - May 24, 2016) -
Data From Phase 2 Trial of Prurisol for Psoriasis to Be Unblinded Next Week, Top-Line Results to Follow
Marketwire Canada - Wed May 11, 8:30AM CDT
BEVERLY, MA--(Marketwired - May 11, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the clinical database for the Phase 2 clinical trial of Prurisol for the treatment of mild-to-moderate chronic plaque psoriasis is expected to be "unblinded" next week. Once the blind is removed, data from each of the four arms of the trial (one placebo arm, three oral dosing regimens of Prurisol) will be reviewed and analyzed to evaluate the safety and efficacy of Prurisol. Cellceutix expects to release top-line data from the study approximately one week after the blind is removed.
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 5.64 (-0.23), CBMG: 14.07 (-0.21), OCAT: 8.47 (+0.01), ZBH: 127.78 (-0.24), PFE: 34.98 (-0.21), LLY: 79.06 (-0.72), GSK: 44.16 (-0.33), GLPG: 53.53 (+0.12), AXSM: 7.54 (+0.12), OMER: 11.34 (-0.20), CANF: 2.23 (-0.02), AST: 2.90 (-0.05), AKTX: 10.57 (-0.43)
Cellceutix Institutes "Database Soft Lock" on Its Phase 2 Psoriasis Clinical Trial, Top Line Results Anticipated in May; Additional Company Updates
Marketwired - Tue Apr 19, 9:30AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to inform shareholders that the clinical database for Prurisol's Phase 2 FDA trial for mild-to-moderate chronic plaque psoriasis has instituted a "Database Soft Lock."
Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer
Marketwired - Thu Mar 31, 8:02AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the latest laboratory research on the Company's anti-cancer drug Kevetrin showed that Kevetrin did not inhibit or induce cytochrome P450 enzymes in vitro. Based upon the documented relationship of P450 and certain potential drug-drug interactions, this positive data is central to the planned Phase 2 clinical trial where Kevetrin will be used in a combination therapy for the treatment of ovarian cancer.
Anthrax Market Pipeline Global Review Research Report for H2 2015
PR Newswire - Thu Mar 17, 9:00PM CDT
The "Anthrax - Pipeline Review, H2 2015" market research report provides an overview of the Anthrax's therapeutic pipeline and helps enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
DVAX: 16.24 (+0.08), TTPH: 3.99 (-0.02), ADRO: 15.11 (-0.09), EBS: 28.01 (+0.09), UTHR: 126.92 (+1.30), BMY: 59.29 (+0.61), PFNX: 8.60 (-0.29), PIP: 2.58 (unch), IBIO: 0.66 (-0.01), OGEN: 0.82 (+0.10)
Cellceutix Concludes Last Patient Visit in Phase 2 FDA Trial of Oral Dosed Prurisol in Patients With Mild-to-Moderate Chronic Plaque Psoriasis
Marketwired - Thu Mar 17, 9:01AM CDT
Cellceutix (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce the conclusion of the last patient visit in its randomized, double-blind Phase 2 trial of orally-administered Prurisol for the treatment of mild to moderate chronic plaque psoriasis. The unblinding of the study and top-line data is expected to be available in May. Although the data is still blinded, there were no safety items of concern.
CELGZ: 1.11 (-0.12)
Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer
Marketwired - Wed Feb 10, 1:23PM CST
Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that Cellceutix executives met this week with staff of the FDA Division of Oncology Products 1 to discuss the Kevetrin Phase 1 study data, as well as a proposed design of a planned Phase 2 trial in patients with ovarian cancer that have resistance to platinum-based therapy.
Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data
Marketwire Canada - Wed Aug 03, 8:30AM CDT
BEVERLY, MA--(Marketwired - August 03, 2016) - Cellceutix Corporation, (OTC: CTIX) ("the Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to provide topline data on the completed Phase 1 clinical trial of Kevetrin for the treatment of advanced solid tumors, which are among the hardest-to-treat types of cancers. Cellceutix Announces Dismissal of Class Action Lawsuit Filed by Rosen Law Firm
Marketwire Canada - Thu Jun 09, 9:51AM CDT
BEVERLY, MA--(Marketwired - June 09, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that, yesterday, the U.S. District Court for the Southern District of New York granted the Company's motion to dismiss the securities class action lawsuit brought against the Company by a plaintiff represented by the Rosen Law Firm. Cellceutix Announces Database Lock in Phase 1 Trial of Kevetrin, a Promising New Cancer Treatment That Activates p53
Marketwired - Mon Jun 06, 6:01AM CDT
BEVERLY, MA--(Marketwired - June 06, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to announce that the study database from the Phase 1 trial of Kevetrin (thioureidobutyronitrile) for advanced solid tumors will be "soft locked" this week. These locked results are the final protocol requirement for the study of Kevetrin in its next clinical trial and will be added to the already prepared documentation for submission to the U.S. Food and Drug Administration ("FDA" in support of the planned Phase 1b/2 trial of Kevetrin in ovarian cancer patients with resistance to platinum-based therapies. Cellceutix is developing Kevetrin under an Orphan Drug designation from the FDA. Cellceutix Releases Pharmacokinetics Data From Phase 2 Trial of Prurisol for Treating Psoriasis; Data Complements Efficacy Data Reported Last Week
Marketwired - Tue May 31, 6:00AM CDT
BEVERLY, MA--(Marketwired - May 31, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to announce that the pharmacokinetics (PK) data on the recently completed Phase 2 trial of Prurisol as a novel oral treatment for plaque psoriasis has been received and is starting to be analyzed. Cellceutix Provides Additional Insight Into Successful Phase 2 Trial for Treating Psoriasis
Marketwire Canada - Thu May 26, 6:01AM CDT
BEVERLY, MA--(Marketwired - May 26, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, today provides additional insight into the successfully completed Phase 2 trial of Prurisol as a new oral therapy for mild to moderate plaque psoriasis. Cellceutix Phase 2 Trial of Prurisol for Mild to Moderate Psoriasis Meets Primary Endpoint
Marketwired - Tue May 24, 9:01AM CDT
BEVERLY, MA--(Marketwired - May 24, 2016) -
Data From Phase 2 Trial of Prurisol for Psoriasis to Be Unblinded Next Week, Top-Line Results to Follow
Marketwire Canada - Wed May 11, 8:30AM CDT
BEVERLY, MA--(Marketwired - May 11, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the clinical database for the Phase 2 clinical trial of Prurisol for the treatment of mild-to-moderate chronic plaque psoriasis is expected to be "unblinded" next week. Once the blind is removed, data from each of the four arms of the trial (one placebo arm, three oral dosing regimens of Prurisol) will be reviewed and analyzed to evaluate the safety and efficacy of Prurisol. Cellceutix expects to release top-line data from the study approximately one week after the blind is removed. Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 5.64 (-0.23), CBMG: 14.07 (-0.21), OCAT: 8.47 (+0.01), ZBH: 127.78 (-0.24), PFE: 34.98 (-0.21), LLY: 79.06 (-0.72), GSK: 44.16 (-0.33), GLPG: 53.53 (+0.12), AXSM: 7.54 (+0.12), OMER: 11.34 (-0.20), CANF: 2.23 (-0.02), AST: 2.90 (-0.05), AKTX: 10.57 (-0.43)
Cellceutix Institutes "Database Soft Lock" on Its Phase 2 Psoriasis Clinical Trial, Top Line Results Anticipated in May; Additional Company Updates
Marketwired - Tue Apr 19, 9:30AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to inform shareholders that the clinical database for Prurisol's Phase 2 FDA trial for mild-to-moderate chronic plaque psoriasis has instituted a "Database Soft Lock." Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer
Marketwired - Thu Mar 31, 8:02AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the latest laboratory research on the Company's anti-cancer drug Kevetrin showed that Kevetrin did not inhibit or induce cytochrome P450 enzymes in vitro. Based upon the documented relationship of P450 and certain potential drug-drug interactions, this positive data is central to the planned Phase 2 clinical trial where Kevetrin will be used in a combination therapy for the treatment of ovarian cancer. Anthrax Market Pipeline Global Review Research Report for H2 2015
PR Newswire - Thu Mar 17, 9:00PM CDT
The "Anthrax - Pipeline Review, H2 2015" market research report provides an overview of the Anthrax's therapeutic pipeline and helps enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
DVAX: 16.24 (+0.08), TTPH: 3.99 (-0.02), ADRO: 15.11 (-0.09), EBS: 28.01 (+0.09), UTHR: 126.92 (+1.30), BMY: 59.29 (+0.61), PFNX: 8.60 (-0.29), PIP: 2.58 (unch), IBIO: 0.66 (-0.01), OGEN: 0.82 (+0.10)
Cellceutix Concludes Last Patient Visit in Phase 2 FDA Trial of Oral Dosed Prurisol in Patients With Mild-to-Moderate Chronic Plaque Psoriasis
Marketwired - Thu Mar 17, 9:01AM CDT
Cellceutix (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce the conclusion of the last patient visit in its randomized, double-blind Phase 2 trial of orally-administered Prurisol for the treatment of mild to moderate chronic plaque psoriasis. The unblinding of the study and top-line data is expected to be available in May. Although the data is still blinded, there were no safety items of concern. CELGZ: 1.11 (-0.12)
Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer
Marketwired - Wed Feb 10, 1:23PM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that Cellceutix executives met this week with staff of the FDA Division of Oncology Products 1 to discuss the Kevetrin Phase 1 study data, as well as a proposed design of a planned Phase 2 trial in patients with ovarian cancer that have resistance to platinum-based therapy. 
